A Phase I trial of the small non-peptide GLP-1 receptor agonist danuglipron in 98 patients with type 2 diabetes found that it had a similar glucose-lowering ability as the clinically used GLP-1 receptor agonists and was well tolerated during the 4 week study period [43]. Here, GLP1R is linked to type 2 diabetes mellitus.